Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

1.57USD
20 Aug 2018
Change (% chg)

$-0.08 (-4.85%)
Prev Close
$1.65
Open
$1.66
Day's High
$1.68
Day's Low
$1.55
Volume
99,723
Avg. Vol
110,810
52-wk High
$11.41
52-wk Low
$0.83

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $23.48
Shares Outstanding(Mil.): 14.23
Dividend: --
Yield (%): --

Financials

  GEMP.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -2.50 -- --
ROI: -145.42 2.89 12.63
ROE: -178.89 1.65 14.82

BRIEF-Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58

* GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 08 2018

BRIEF-Gemphire Therapeutics Names Steven Gullans CEO

* GEMPHIRE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF STEVEN GULLANS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

May 03 2018

BRIEF-Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​

* GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

Earnings vs. Estimates